GMDP academy
ISSUE 68 • AUG. 29, 2025

MEDICAL AFFAIRS AS A STRATEGIC BUSINESS PARTNER

Once seen mainly as a support role, Medical Affairs is now a strategic partner in shaping therapy adoption, evidence generation, and patient access. This shift reflects the growing complexity of treatments, demand for real-world evidence, and heightened patient engagement.

📖 Read the full article: Medical Affairs as a Strategic Business Partner: From Support Function to Value Driver

TABLE OF CONTENTS

🚨 Final Call for Enrollment: Modules 7 & 8 Begin Soon!

Time is running out to join GMDP Academy's next two transformative learning opportunities—**Leadership in Medicines Development (Module 7)** and **Digital Technology in Medicines Development (Module 8)**. Orientation for both begins in September, and seats are filling fast!

📌 **Apply by September 15, 2025 to future-proof your career!**

👉 Start Your Application

✅ **Module 7**: Empower your leadership journey with skills tailored to the pharmaceutical and biotech sectors. Build a personalized leadership development plan and gain tools to influence cross-functional decision-making.

✅ **Module 8:** Stay ahead with cutting-edge insights on AI, big data, and digital innovation in drug development. Explore how emerging technologies are transforming patient engagement, clinical trials, and regulatory strategy.

🔗 **Fully Online** | 🌍 **Global Network** | ⏳ **Deadlines Approaching!**

📅 **Orientation Begins**: September 29 (Module 7)
September 22 (Module 8)

AI BREAKTHROUGH DESIGNS CANCER-TARGETING DRUG CANDIDATES WITHOUT PRIOR DATA

Drug discovery is often slow, costly, and uncertain. Researchers at KAIST have introduced BInD (Bond and Interaction-Generating Diffusion Model), an AI system that can design new drug candidates directly from a protein's 3D structure — without relying on prior knowledge of binding molecules.

BInD stands out by generating molecules and modeling how they interact with a target at the same time, while following real chemical rules. Early results show promise in oncology, where it successfully designed molecules that selectively target mutated EGFR proteins linked to cancer.

This innovation could accelerate development, reduce trial-and-error, and open the door to more precise, effective treatments. [1,2]



👉Read more about KAIST's BInD breakthrough and its potential to transform drug discovery here.

TURNING THE TIDE AGAINST MALARIA: HOW A SIMPLE CHEMICAL SHIFT COULD SAVE MILLIONS

Malaria continues to take a heavy toll, particularly among children in Sub-Saharan Africa. UCSF researchers have redesigned artefenomel — previously limited by poor solubility — into a fast-dissolving, potent variant that remains effective against resistant strains, offering hope for a more accessible and effective therapy.

This advance underscores the importance of translational science, patient-centered problem-solving, and ethical stewardship in medicines development. GMDP Academy's Certification in Medicines Development, delivered with King's College London, prepares professionals to turn scientific innovation into real-world impact for global health [3, 4, 5, 6].

👉Read more about the breakthrough, and the Academy, here.

WHY GENE AND CELL THERAPIES ARE STALLING AT THE FDA

Why Gene and Cell Therapies Are Stalling at the FDA In 2025, several advanced therapy programs were delayed or rejected by the FDA due to Chemistry, Manufacturing, and Controls (CMC) readiness, not safety or efficacy. From 2020–2024, 74% of FDA Complete Response Letters cited manufacturing or quality deficiencies.

Essential competencies for medicines development professionals include:

- CMC Fundamentals – Development, manufacture, vector platforms, analytical validation
- Regulatory Strategy – Integrating CMC into submissions; interpreting FDA/EMA guidance
- Cross-functional Collaboration – Aligning R&D, manufacturing, and quality; building shared language
- Risk & Change Management – Planning scale-up, tech transfer, comparability testing

Scientific innovation alone isn't enough. GMDP Academy's Certification in Medicines Development (CMD) equips professionals with these skills to navigate regulatory challenges and bring therapies to patients faster [7-11].👉Read more here.

UNLOCKING NEW HORIZONS IN OSTEOARTHRITIS TREATMENT

A landmark study has identified 962 genetic markers and more than 700 potential drug targets for osteoarthritis, highlighting opportunities for drug repurposing and precision therapies. While the findings promise faster, more targeted treatment development, success depends on professionals skilled in translational science, regulatory strategy, and ethical decision-making.

GMDP Academy, in partnership with King's College London, prepares medicines development professionals with these competencies, ensuring genomic discoveries can be translated into safe, effective, and equitable therapies [12-15].

👉Read more here.

REFERENCES

1. KAIST. (2025, August 11). AI automatically designs optimal drug candidates for cancer-targeting mutations. Phys.org. https://phys.org/news/2025-08-ai-automatically-optimal-drug-candidates.html
2. Lee, J., Zhung, W., Seo, J., & Kim, W. Y. (2025). BInD: Bond and interaction-generating diffusion model for multi-objective structure-based drug design. Advanced Science. Advance online publication. https://doi.org/10.1002/advs.202502702
3. Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (2021). Editorial: Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406
4. Silva, H., Stonier, P., Chopra, P., Coots, J., Criscuolo, D., Guptha, S., Jones, S., Kerpel-Fronius, S., Kesselring, G., Luria, X., Morgan, D., Power, E., Salek, S., Silva, G., Suto, T., Thakker, K., & Vandenbroucke, P. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King's College London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036
5. University of California – San Francisco. (2025, August 11). This chemical trick could turn losing malaria drug into a winner [Press release]. Science Advances. https://www.eurekalert.org/news-releases/1094239
6. World Health Organization. (2024). World malaria report 2024. World Health Organization. https://www.who.int/publications/i/item/9789240089752
7. Pharma Manufacturing. (2025, July 14). FDA's CRLs reveal 74% of applications rejected for quality/manufacturing issues. https://www.pharmamanufacturing.com/all-articles/article/55302937/fdas-crls-reveal-74-of-applications-rejected-for-quality-manufacturing-issues
8. FDA. (2025, July 10). FDA embraces radical transparency by publishing Complete Response Letters. https://www.fda.gov/news-events/press-announcements/fda-embraces-radical-transparency-publishing-complete-response-letters
9. Pharmaceutical Technology. (2025, July 25). CMC and analytical gaps in CRLs: Why they persist despite FDA guidance and how you can position yourself for success. https://www.pharmtech.com/view/cmc-and-analytical-gaps-in-crls-why-they-persist-despite-fda-guidance-and-how-you-can-position-yourself-for-success
10. Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (2021). Editorial: Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406
11. Foster, B. (2025, August 3). Why gene and cell therapies are stalling at the FDA. Drug Discovery News. https://www.drugdiscoverynews.com/game-changer-drug-is-the-first-to-tackle-overeating-in-prader-willi-syndrome-16355
12. GMDP Academy. (2024). GMDP Academy Offerings 2024/2025. https://info.gmdpacademy.org/course-catalog
13. Hatzikotoulas, K., Southam, L., Stefansdottir, L., Boer, C. G., McDonald, M.-L., Pett, J. P., … & Zeggini, E. (2025). Translational genomics of osteoarthritis in 1,962,069 individuals. Nature. https://doi.org/10.1038/s41586-025-08771-z
14. Silva, H., Stonier, P., Kerpel-Fronius, S., & Dubois, D. (2021). Editorial: Grand Challenges in Pharmaceutical Medicine: Competencies and Ethics in Medicines Development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406
15. University of Maryland School of Medicine. (2025, April 30). $486 Billion Problem: Groundbreaking Study Could Slash Osteoarthritis Costs. SciTechDaily. https://scitechdaily.com/486-billion-problem-groundbreaking-study-could-slash-osteoarthritis-costs/

Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

Media Manager: Whitney English

Editorial Board: Pravin Chopra, Jacob Coots

Operations Office: Amanda Schmitt, Gustavo Silva, Kit Vale

CONTACT US:

420 Lexington Ave. Ste. 300
New York, NY 10170

(332) 333-2438